Maciej Dulewicz

Mar 22, 2024 | nature.com | Fernando Gonzalez-Ortiz |Maciej Dulewicz |Vijay R. Varma |Tammaryn Lashley |Gunnar Brinkmalm |Susan M. Resnick | +6 more

AbstractBlood phosphorylated tau (p-tau) biomarkers, including p-tau217, show high associations with Alzheimer’s disease (AD) neuropathologic change and clinical stage. Certain plasma p-tau217 assays recognize tau forms phosphorylated additionally at threonine-212, but the contribution of p-tau212 alone to AD is unknown. We developed a blood-based immunoassay that is specific to p-tau212 without cross-reactivity to p-tau217. Here, we examined the diagnostic utility of plasma p-tau212.